Get the Daily Brief
Latest Biotech News
AI Model GREmLN Captures Gene Regulatory Networks to Enhance Disease Understanding
Researchers at Columbia University and the Chan Zuckerberg Initiative unveiled GREmLN, a novel graph-based artificial intelligence model designed to capture complex gene regulatory networks from...
New Radiopharma Startups Secure Major Funding Rounds to Advance Diagnostics and Therapeutics
Radiopharmaceutical biotech companies Nuclidium and Actithera have raised sizable capital rounds to develop novel diagnostic and therapeutic platforms. Swiss-German Nuclidium secured $99 million...
Jazz Names Renée Galá Successor as CEO; Executive Moves Stir Biotech Sector
Jazz Pharmaceuticals announced the promotion of current President and Chief Operating Officer Renée Galá as its incoming CEO, succeeding co-founder Bruce Cozadd in August. This leadership...
Intranasal Monoclonal Antibody Reduces Pollen Allergy and Asthma Symptoms in Mouse Model
Researchers at Kazakh National Agrarian Research University engineered an intranasal monoclonal antibody targeting mugwort pollen allergen that effectively prevented hay fever and asthma symptoms...
Actithera’s FAP-Targeted Radiopharmaceutical Raises $75 Million in Series A
Danish biotech Actithera A/S has closed a $75.5 million Series A financing round to fund early clinical development of its lead radiopharmaceutical candidate targeting fibroblast activation...
Merck’s $10 Billion Acquisition: Reinforcing Respiratory Portfolio with Verona Pharma
Merck & Co. has entered a definitive $10 billion agreement to acquire London-based Verona Pharma, bolstering its cardiopulmonary drug portfolio with Ohtuvayre (ensifentrine), a first-in-class...
AbbVie’s $700 Million Investment: Securing Trispecific Antibody for Multiple Myeloma
AbbVie has inked a landmark deal worth $700 million upfront with IGI Therapeutics for exclusive rights to ISB-2001, a trispecific antibody targeting BCMA, CD38, and CD3, showing promise in...
FDA’s Novel Transparency Effort: Publishing Drug Rejection Letters for Approved Products
The U.S. Food and Drug Administration (FDA) has initiated a historic transparency measure by releasing over 200 complete response letters (CRLs) issued to drug and biologic sponsors whose products...
Pfizer and Astellas Expand Xtandi Label With New Survival Benefits in Early Prostate Cancer
Pfizer and Astellas have announced encouraging phase 3 data from the EMBARK trial demonstrating that Xtandi (enzalutamide), in combination with leuprolide, significantly improves overall survival...
Center for Pediatric CRISPR Therapies Funded to Advance Ultra-Rare Disease Gene Editing
The Chan Zuckerberg Initiative (CZI) and Innovative Genomics Institute (IGI) have jointly funded the creation of the Center for Pediatric CRISPR Cures, aiming to develop personalized CRISPR-based...
AI Advances in Protein and Cell Modeling Enhance Drug Discovery and Biological Insights
Researchers are leveraging artificial intelligence to revolutionize protein modeling and cellular behavior predictions, significantly accelerating drug discovery. Microsoft Research has unveiled...
Cell Therapy Setback: FDA Rejects Capricor’s Duchenne Muscular Dystrophy Treatment
The FDA has issued a Complete Response Letter (CRL) rejecting Capricor Therapeutics’ marketing application for deramiocel, a cell therapy targeting cardiomyopathy in Duchenne muscular dystrophy...
Innovative Diagnostic and Therapeutic Technologies Emerge Across Cancer, Allergy, and Obesity
Several novel biotechnological advancements signal progress in diagnostics and treatments spanning oncology, immunology, and metabolic disorders. University of Chicago spinout OrisDx is preparing...
Continuous Biomanufacturing and AI Innovations Drive Efficiency in Drug Development
The biomanufacturing sector is witnessing shifts towards continuous production models promising higher yields, lower costs, and environmental benefits. Companies like Enzene Biosciences employ...
Merck's Blockbuster Respiratory Buyout Spurs Growth
Merck & Co. announced a $10 billion acquisition of London-based Verona Pharma, gaining the inhaled COPD drug Ohtuvayre, a first-in-class dual inhibitor combining bronchodilator and...
AbbVie Secures Trispecific Antibody Targeting Multiple Myeloma
AbbVie inked a sizable $700 million upfront deal for rights to ISB-2001, an early-stage trispecific antibody developed by IGI Therapeutics designed to bind three targets on multiple myeloma cells....
FDA Unveils Complete Response Letters to Boost Transparency
In a historic policy shift, the FDA released more than 200 complete response letters (CRLs) issued from 2020 to 2024 concerning drug application rejections. The letters, although redacted and...
AI-Powered Protein Design Targets Drug-Resistant Bacteria
Australian scientists at Monash University have leveraged artificial intelligence to design novel proteins that inhibit membrane transporters essential for antibiotic-resistant Escherichia coli....
Radiopharmaceutical Sector Attracts Major Funding Rounds
European radiopharma companies are raising substantial capital with funding rounds exceeding $75 million. Notably, Nuclidium AG secured $99 million to advance copper isotope-based diagnostic and...
AI and Biotech Collaborate on Accelerated Drug Discovery
Revolution Medicines formed a multi-year collaboration with AI-driven drug discovery company Iambic Therapeutics to advance oncology target discovery using AI models. Iambic will train its...